AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 9275368
Drug: Artesunate at
RxNorm normalized name: Artesunate
DrugBank: Artesunate (DB09274)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Artesunate at a dose of 6 mg/kg once a week for 8 weeks
Trial: 6853785
Drug: Diflorasone diacetate
RxNorm normalized name: Diflorasone Diacetate
DrugBank: Diflorasone (DB00223)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Diflorasone diacetate (DD) ointment
Trial: 30814413
Drug: Okara (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Okara (60 g/day for 2 weeks)
Trial: 25483421
Drug: Chlorhexidine (CHD)
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chlorhexidine (CHD) solution, wiped till day seven of life
Trial: 25483421
Drug: Chlorhexidine (CHD)
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chlorhexidine (CHD) solution
Trial: 24819981
Drug: Total urinary
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total urinary resveratrol metabolites (mean concentration 7.08 nmol/g of creatinine)
Trial: 16813032
Drug: Intranasal aqueous
RxNorm normalized name: ethylcellulose aqueous dispersion type A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal aqueous triamcinolone spray
Trial: 6381065
Drug: Intravenous and
RxNorm normalized name: immune globulin intravenous and subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous and oral mexiletine
Trial: 26309191
Drug: MAGE-A3 immunotherapeutic
RxNorm normalized name: Kitasamycin A3
DrugBank: Josamycin (DB01321)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MAGE-A3 immunotherapeutic (300 μg recombinant MAGE-A3 formulated with AS15) administered concurrently with standard cisplatin/vinorelbine chemotherapy (cohort 1)
Trial: 26309191
Drug: MAGE-A3 immunotherapeutic
RxNorm normalized name: Kitasamycin A3
DrugBank: Josamycin (DB01321)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MAGE-A3 immunotherapeutic administered after standard chemotherapy (cohort 2)
Trial: 26309191
Drug: MAGE-A3 immunotherapeutic
RxNorm normalized name: Kitasamycin A3
DrugBank: Josamycin (DB01321)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MAGE-A3 immunotherapeutic administered without standard chemotherapy (cohort 3)
Trial: 26309191
Drug: MAGE-A3 immunotherapeutic
RxNorm normalized name: Kitasamycin A3
DrugBank: Josamycin (DB01321)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MAGE-A3 immunotherapeutic administered after standard radiotherapy and/or chemotherapy (cohort 4)
Trial: 27193080
Drug: Intravenous tramadol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous tramadol (2 mg/kg)
Trial: 19401664
Drug: Peritonsillar infiltration
RxNorm normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peritonsillar infiltration of tramadol (2 mg/kg in 2 ml normal saline)
Trial: 15523663
Drug: Periconceptional multivitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Periconceptional multivitamin supplementation containing folic acid (0.8 mg)
Trial: 11736724
Drug: Omeprazole (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole (20 mg daily for 8 days)
Trial: 11736724
Drug: Rabeprazole (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rabeprazole (20 mg daily for 8 days)
Trial: 9369816
Drug: Lactated Ringer's
RxNorm normalized name: LACTATED RINGER'S
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lactated Ringer's solution with 5% glucose (n = 48)
Trial: 9369816
Drug: Lactated Ringer's
RxNorm normalized name: LACTATED RINGER'S
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lactated Ringer's solution without glucose (n = 43)
Trial: 26590384
Drug: Mean on-treatment
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mean on-treatment SBP 130-139 mmHg or DBP 80-89 mmHg
Trial: 18568228
Drug: Mechanical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mechanical treatment - 0.4 mm beads
Trial: 18568228
Drug: Mechanical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mechanical treatment - 0.6 mm beads
Trial: 18568228
Drug: Chemical/mechanical treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemical/mechanical treatment - 0.4 mm beads
Trial: 18568228
Drug: Chemical/mechanical treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemical/mechanical treatment - 0.6 mm beads
Trial: 16238901
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg intravenous test dose of paclitaxel or docetaxel
Trial: 16238901
Drug: Full dose
RxNorm normalized name: BayRHo-D Full Dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full dose of paclitaxel or docetaxel without a test dose
Trial: 7579056
Drug: Cyclosporine monotherapy
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporine monotherapy (CsA)
Trial: 2284832
Drug: Hydrocolloid dressing
RxNorm normalized name: hydrocolloid dressing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocolloid dressing containing anthralin (0.02 to 0.20 mg/cm2)
Trial: 2284832
Drug: Short-contact therapy
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-contact therapy with anthralin alone
Trial: 25634195
Drug: 3-L split-dose
RxNorm normalized name: 3-(L-MENTHOXY)-2-METHYLPROPANE-1,2-DIOL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-L split-dose PEG
Trial: 15651179
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of amphotericin B and fluconazole
Trial: 15651179
Drug: Echinocandins in
RxNorm normalized name: Echinocandin B, 1-((4R,5R)-4-hydroxy-N2-((4''-(pentyloxy)(1,1':4',1''-terphenyl)-4-yl)carbonyl)-5-(2-(trimethylammonio)ethoxy)-l-ornithine)-4-((4S)-4-hydroxy-4-(4-hydroxyphenyl)-l-allothreonine)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Echinocandins in combination with triazoles
Trial: 15651179
Drug: Addition of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Addition of echinocandin to monotherapy for aspergillosis
Trial: 9756589
Drug: No acupuncture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No acupuncture treatment (control group)
Trial: 31828291
Drug: High-dose trivalent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose trivalent vaccine
Trial: 31828291
Drug: Standard-dose quadrivalent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose quadrivalent vaccine
Trial: 17976882
Drug: Escitalopram 10-20
RxNorm normalized name: escitalopram 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escitalopram 10-20 mg/day for 12 weeks
Trial: 12851511
Drug: Oral hormone
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral hormone replacement therapy (2 mg daily of 17beta-estradiol plus 10 mg dydrogesterone daily for 14 days of each 28-day cycle)
Trial: 10541423
Drug: Fexofenadine HCl
RxNorm normalized name: fexofenadine HCl
DrugBank: Fexofenadine (DB00950)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fexofenadine HCl 180 mg QD
Trial: 31201653
Drug: Brief cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brief cognitive behavioral therapy (bCBT)
Trial: 19320663
Drug: Inhaled insulin
RxNorm normalized name: insulin, regular, human Inhalation Powder [Afrezza]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled insulin three times daily before meals
Trial: 19320663
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine administered in the morning before breakfast
Trial: 11332784
Drug: Behavioral treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral treatment
Trial: 11239727
Drug: 6-session cognitive-behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6-session cognitive-behavioral therapy (CBT) program
Trial: 9402774
Drug: Subcutaneous octreotide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous octreotide 50 micrograms twice daily for 6 months with programmed injection sclerotherapy
Trial: 9402774
Drug: Programmed injection
RxNorm normalized name: Immunoglobulin G4, anti-programmed cell death protein 1 (PDCD1) (humanized clone ABT1 gamma4-chain), disulfide with humanized clone ABT1 kappa-chain, dimer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Programmed injection sclerotherapy alone
Trial: 30522512
Drug: Oral health
RxNorm normalized name: CETYLPYRIDINIUM CHLORIDE 0.07 g in 100 mL ORAL RINSE [Assured Oral Health Fresh Mint]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral health intervention including oral health education sessions and daily oral self-care under caregiver supervision.
Trial: 22820824
Drug: Deep heating
RxNorm normalized name: Mentholatum Deep Heating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deep heating therapy (DHT) via local microwave diathermy (three 30‐min sessions a week for four weeks)
Trial: 22820824
Drug: Superficial heating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Superficial heating therapy (SHT) via application of hot packs (three 30‐min sessions a week for four weeks)
Trial: 23185342
Drug: Expectation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Expectation of taking an immunosuppressant
Trial: 15985509
Drug: Acupuncture at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture at the Quchi (LI11) acupoint thrice weekly for 1 month
Trial: 15985509
Drug: Acupuncture at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture at a non‐acupoint 2 cm lateral to Quchi (LI11) thrice weekly for 1 month
Trial: 9154882
Drug: Isoniazid (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoniazid (oral administration)
Trial: 21690572
Drug: Vinorelbine or
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vinorelbine or paclitaxel-containing chemotherapy
Trial: 11090595
Drug: 6.0 g
RxNorm normalized name: MENTHOL 6.0 g in 100 g TOPICAL GEL [RockSauce ICE]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6.0 g fish oil daily for 6 weeks
Trial: 3888046
Drug: Synthetic androgen
RxNorm normalized name: Synthetic camphor
DrugBank: Synthetic camphor (DB14156)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Synthetic androgen fluoxymesterone for 3 days before and on the day of chemotherapy
Trial: 3888046
Drug: Aminoglutethimide and
RxNorm normalized name: Aminoglutethimide
DrugBank: Aminoglutethimide (DB00357)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aminoglutethimide and hydrocortisone plus cyclic chemotherapy
Trial: 14732657
Drug: 40% urea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40% urea cream applied to half of the treatment area
Trial: 14732657
Drug: topical 3%
RxNorm normalized name: sulfur topical 3% topical soap
FDA approved: no
EMA approved: no
PMDA approved: no
Description: topical 3% lidocaine hydrochloride applied 45 minutes before treatment
Trial: 14732657
Drug: vehicle cream
RxNorm normalized name: vehicle cream base no.160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vehicle cream applied to half of the treatment area
Trial: 14732657
Drug: vehicle cream
RxNorm normalized name: vehicle cream base no.160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vehicle cream applied 45 minutes before treatment
Trial: 9563529
Drug: Delayed laparoscopic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed laparoscopic cholecystectomy after initial medical treatment
Trial: 25802354
Drug: Topical corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical corticosteroids (TCSs)
Trial: 23415344
Drug: Short-term educational
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term educational intervention (24 units) in human biology based on Evidence-based Medicine (EbM) and Good Scientific Practice (GSP)
Trial: 16107866
Drug: Citalopram 20
RxNorm normalized name: citalopram 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram 20 mg oral daily
Trial: 14871283
Drug: Balsalazide (750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Balsalazide (750 mg capsules, two capsules twice daily, increased by 750 mg increments to a maximum of 6 g for up to 7 days)
Trial: 10096243
Drug: FAC/FEC treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FAC/FEC treatment
Trial: 30829429
Drug: Fentanyl 1
RxNorm normalized name: fentanyl 1.2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl 1 µg kg‐1 h‐1
Trial: 12521277
Drug: Calcium lactate
RxNorm normalized name: Calcium Lactate
DrugBank: Calcium lactate (DB13231)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium lactate (3 g daily)
Trial: 9806564
Drug: Fixed-dose regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose regimen
Trial: 9806564
Drug: Low-dose step-up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose step-up regimen
Trial: 25127878
Drug: Qigong intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Qigong intervention (2-hour group training twice a week for 6 weeks, 1-hour follow-up group session once a week for 4 months, 30-minute self-practice daily for 5.5 months)
Trial: 24321402
Drug: Pre-conception treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-conception treatment including dental scaling and root planning, supragingival prophylaxis, and oral hygiene education
Trial: 24321402
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group receiving supragingival prophylaxis and oral hygiene education
Trial: 3886274
Drug: Group II
RxNorm normalized name: Platelet group IIa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group II (treatment)
Trial: 10817793
Drug: Cisplatin-based chemotherapy
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin-based chemotherapy (3 courses)
Trial: 6149824
Drug: Treadmill exercise
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treadmill exercise test on placebo and beta-blocker in patients with CAD
Trial: 21911720
Drug: Venlafaxine 75
RxNorm normalized name: venlafaxine 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venlafaxine 75 mg
Trial: 23621628
Drug: Trabeculectomy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trabeculectomy with intracameral and subconjunctival injections of bevacizumab (1.25 mg/0.05 mL) and subconjunctival injections of 5‐FU (5.0 mg/0.5 mL)
Trial: 23621628
Drug: Trabeculectomy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trabeculectomy with 5‐FU (5.0 mg/0.5 mL)
Trial: 9038037
Drug: Felodipine ER
RxNorm normalized name: Felodipine ER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Felodipine ER 5 mg (F5)
Trial: 9038037
Drug: Nifedipine Retard
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nifedipine Retard 10 mg (N20)
Trial: 9038037
Drug: Nifedipine Retard
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nifedipine Retard 20 mg (N40)
Trial: 7557846
Drug: no therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: no therapy (control)
Trial: 8692739
Drug: Intravenous montelukast
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous montelukast sodium (3, 9, and 18 mg)
Trial: 8692739
Drug: Oral montelukast
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral montelukast sodium (10 mg) in females
Trial: 30638739
Drug: Four-oil lipid
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four-oil lipid emulsion (30% soybean oil, 30% medium-chain triglycerides, 25% olive oil, 15% fish oil) administered continuously for 5 days, FO dose of 0.09-0.22 g/kg body weight.
Trial: 30638739
Drug: 100% soybean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100% soybean oil lipid emulsion administered continuously for 5 days.
Trial: 30680401
Drug: SPR periodontal
RxNorm normalized name: betamethasone
DrugBank: Betamethasone phosphate (DB14669)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SPR periodontal basic treatment
Trial: 20617588
Drug: Human serum
RxNorm normalized name: Human serum albumin
DrugBank: Albumin human (DB00062)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human serum immunoglobulin treatment
Trial: 11833075
Drug: High-dose iodized
RxNorm normalized name: calcium iodized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose iodized oil TACE (more than 20 mL Lipiodol)
Trial: 11833075
Drug: Routine dose
RxNorm normalized name: Peace Out Acne Hero Routine KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine dose iodized oil TACE (5-15 mL Lipiodol)
Trial: 10362425
Drug: Inhaled nitric
RxNorm normalized name: nitric oxide Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled nitric oxide at doses of < or =5 ppm
Trial: 10362425
Drug: Prolonged inhaled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged inhaled nitric oxide at doses of < or =20 ppm
Trial: 7722713
Drug: Nutritional supplementation
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutritional supplementation (specifics on dosage and duration not available)
Trial: 2040466
Drug: Cisapride (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisapride (10 mg) three times a day for three days
Trial: 6389470
Drug: Intravenous acyclovir
RxNorm normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous acyclovir (5 mg/kg three times daily for five days)
Trial: 6389470
Drug: Oral acyclovir
RxNorm normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral acyclovir (400 mg five times daily for five days)
Trial: 8708685
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin injections
Trial: 27281233
Drug: Vacuum sealing
RxNorm normalized name: GOLDEN SEAL
DrugBank: Goldenseal (DB16594)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vacuum sealing drainage (VSD) and antibiotic‐loaded bone cement
Trial: 24932979
Drug: Control: Lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control: Lidocaine with epinephrine (1.84 mL solution: 36.8 mg lidocaine with 18.4 μg epinephrine)
Trial: 22227226
Drug: robenacoxib (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: robenacoxib (2 mg/kg)
Trial: 22227226
Drug: meloxicam (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: meloxicam (0.3 mg/kg)
Trial: 7799476
Drug: Placebo (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (1 g of calcium carbonate and 4 mg of sodium chloride)
Trial: 24848384
Drug: Low-dose ketamine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose ketamine infusion (6 μg/kg/minute)
Trial: 23731195
Drug: Active formulation
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active formulation containing licochalcone A, l-carnitine and 1,2-decanediol applied twice daily for 8 weeks
Trial: 20008943
Drug: Selective serotonin
RxNorm normalized name: Selective serotonin (5HT1) agonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective serotonin reuptake inhibitor (SSRI) or venlafaxine, with or without cognitive-behavioral therapy (CBT)
Trial: 10818263
Drug: NPY (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NPY (both doses)
Trial: 8815021
Drug: No antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antibiotic prophylaxis (Group B, n = 50)
Trial: 1836894
Drug: Fluoxetine 40
RxNorm normalized name: fluoxetine 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine 40 mg
Trial: 6441721
Drug: Vasoactive intestinal
RxNorm normalized name: Vasoactive intestinal peptide
DrugBank: Vasoactive intestinal peptide (DB18634)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vasoactive intestinal polypeptide (VIP) infusion in controls
Trial: 6441721
Drug: Vasoactive intestinal
RxNorm normalized name: Vasoactive intestinal peptide
DrugBank: Vasoactive intestinal peptide (DB18634)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vasoactive intestinal polypeptide (VIP) infusion in hyperprolactinaemics
Trial: 29122965
Drug: 20 g
RxNorm normalized name: PEG-20 glyceryl oleate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 g of dairy protein supplementation
Trial: 24240607
Drug: Rifaximin, administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifaximin, administered in cycles of 7-10 days per month over a period of 3 months
Trial: 22321770
Drug: Fidaxomicin (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fidaxomicin (200 mg every 12 h for 10 days)
Trial: 22321770
Drug: Vancomycin (125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vancomycin (125 mg every 6 h for 10 days)
Trial: 27281556
Drug: Letrozole monotherapy
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Letrozole monotherapy
Trial: 21335417
Drug: Tamoxifen monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen monotherapy